Carlsmed (CARL) Common Equity (2024 - 2026)

Carlsmed (CARL) has 3 years of Common Equity data on file, last reported at $92.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 220.41% year-over-year to $92.2 million; the trailing twelve-month figure through Mar 2026 stood at $92.2 million (up 220.41% YoY), and the FY2025 full-year result was $98.9 million, up 239.98% from the prior year.
• Common Equity for Q1 2026 stood at $92.2 million, down from $98.9 million in the prior quarter.
• Across five years, Common Equity topped out at $106.7 million in Q3 2025 and bottomed at -$83.1 million in Q2 2025.
• The 3-year median for Common Equity is -$61.9 million (2024), against an average of -$7.0 million.
• Peak annual rise in Common Equity reached 261.54% in 2025, while the deepest fall reached 43.88% in 2025.
• A 3-year view of Common Equity shows it stood at -$70.6 million in 2024, then soared by 239.98% to $98.9 million in 2025, then decreased by 6.7% to $92.2 million in 2026.
• The last three Common Equity figures came in at $92.2 million (Q1 2026), $98.9 million (Q4 2025), and $106.7 million (Q3 2025), per Business Quant data.

Peer Comparison